HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Steven Grant Selected Research

obatoclax

10/2013Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
12/2012Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
8/2012CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
6/2012Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
5/2012Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
5/2012Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
4/2012Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
11/2009Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Steven Grant Research Topics

Disease

114Neoplasms (Cancer)
07/2022 - 07/2002
82Leukemia
01/2021 - 01/2002
35Multiple Myeloma
07/2022 - 11/2002
26Melanoma (Melanoma, Malignant)
11/2013 - 08/2003
21Carcinoma (Carcinomatosis)
10/2013 - 03/2002
21Mitochondrial Diseases (Mitochondrial Disease)
01/2013 - 01/2002
17Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2020 - 07/2003
14Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
06/2019 - 08/2009
13Hematologic Neoplasms (Hematological Malignancy)
07/2020 - 11/2003
13Myeloid Leukemia (Leukemia, Myelocytic)
12/2015 - 01/2002
12Glioblastoma (Glioblastoma Multiforme)
01/2015 - 07/2003
11Breast Neoplasms (Breast Cancer)
10/2013 - 12/2004
10Glioma (Gliomas)
10/2014 - 08/2003
9Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2019 - 12/2002
9Lymphoma (Lymphomas)
05/2017 - 07/2003
9BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
05/2011 - 07/2004
8B-Cell Lymphoma (Lymphoma, B Cell)
07/2022 - 05/2009
8Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2018 - 06/2010
6Infections
03/2011 - 07/2003
5Prostatic Neoplasms (Prostate Cancer)
05/2012 - 01/2007
4Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2019 - 07/2002
4B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2017 - 12/2002
4Ataxia Telangiectasia (Louis Bar Syndrome)
09/2015 - 04/2003
4Renal Cell Carcinoma (Grawitz Tumor)
11/2013 - 07/2003
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2021 - 12/2009
3Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2017 - 10/2012
3Waldenstrom Macroglobulinemia (Macroglobulinemia)
11/2014 - 09/2011

Drug/Important Bio-Agent (IBA)

58Histone Deacetylase InhibitorsIBA
10/2021 - 02/2002
38Proteins (Proteins, Gene)FDA Link
01/2020 - 01/2002
32Phosphotransferases (Kinase)IBA
07/2022 - 01/2002
29Bortezomib (Velcade)FDA Link
07/2022 - 10/2003
27VorinostatFDA Link
01/2018 - 12/2003
24alvocidib (flavopiridol)IBA
01/2018 - 02/2002
22Proteasome InhibitorsIBA
06/2019 - 10/2003
22Pharmaceutical PreparationsIBA
01/2019 - 07/2003
21Cyclin-Dependent Kinases (cdk Proteins)IBA
03/2014 - 02/2002
20Sorafenib (BAY 43-9006)FDA Link
01/2015 - 10/2005
20InterleukinsIBA
11/2013 - 08/2003
20CaspasesIBA
02/2013 - 03/2002
19CytokinesIBA
01/2020 - 12/2003
19Imatinib Mesylate (Gleevec)FDA Link
01/2015 - 01/2002
197-hydroxystaurosporine (UCN 01)IBA
05/2013 - 05/2002
17Histone Deacetylases (Histone Deacetylase)IBA
01/2016 - 07/2003
17Reactive Oxygen Species (Oxygen Radicals)IBA
01/2013 - 07/2003
15Butyric Acid (Butanoic Acid)IBA
01/2006 - 02/2002
13Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
04/2012 - 11/2002
13Cytochromes c (Cytochrome c)IBA
07/2007 - 01/2002
12Drug CombinationsIBA
06/2017 - 11/2005
122- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamideIBA
04/2012 - 01/2002
11CeramidesIBA
07/2012 - 03/2005
9carfilzomibIBA
10/2019 - 06/2010
8DNA (Deoxyribonucleic Acid)IBA
03/2022 - 07/2003
8obatoclaxIBA
10/2013 - 11/2009
7ABT-737IBA
12/2015 - 01/2007
7Caspase 3 (Caspase-3)IBA
06/2008 - 01/2002
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2022 - 07/2002
6Biological ProductsIBA
08/2018 - 04/2005
6Cytarabine (Cytosar-U)FDA LinkGeneric
09/2015 - 05/2002
6Lapatinib (GW572016)FDA Link
01/2015 - 11/2009
6Caspase 9IBA
10/2013 - 05/2002
6Interleukin-10 (Interleukin 10)IBA
05/2012 - 05/2010
6Cytotoxins (Cytolysins)IBA
01/2012 - 02/2003
6tanespimycin (17AAG)IBA
03/2011 - 09/2003
6Mitogen-Activated Protein KinasesIBA
05/2010 - 01/2002
6Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
05/2010 - 01/2002
6bryostatin 1IBA
10/2006 - 05/2002
6Protein Kinase CIBA
03/2005 - 05/2002
5venetoclaxIBA
07/2020 - 01/2018
5AZD 6244IBA
03/2016 - 03/2008
5OSU 03012IBA
10/2014 - 08/2006
5Small Interfering RNA (siRNA)IBA
09/2014 - 08/2004
5AD 5IBA
11/2013 - 06/2010
5Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
08/2012 - 01/2002
5fludarabineIBA
04/2012 - 12/2002
5entinostat (MS 275)IBA
09/2011 - 07/2003
5Caspase 8 (Caspase-8)IBA
03/2011 - 05/2002
5Heat-Shock Proteins (Heat-Shock Protein)IBA
05/2010 - 09/2003
5NF-kappa B (NF-kB)IBA
03/2010 - 09/2003
5Mitogen-Activated Protein Kinase 3IBA
11/2009 - 02/2005
5U 0126 (UO 126)IBA
11/2009 - 11/2002
4LigandsIBA
07/2022 - 12/2003
4PanobinostatIBA
10/2021 - 04/2012
4belinostatIBA
01/2021 - 01/2008
4Apoptosis Regulatory ProteinsIBA
08/2017 - 02/2006
4romidepsin (FK228)FDA Link
01/2017 - 01/2008
4Valproic Acid (Depakote)FDA LinkGeneric
05/2014 - 08/2009
4Endoplasmic Reticulum Chaperone BiPIBA
03/2014 - 05/2010
4Checkpoint Kinase 1IBA
08/2012 - 12/2006
4RoscovitineIBA
01/2007 - 04/2003
3RNA Polymerase II (RNA Polymerase B)IBA
10/2019 - 04/2013
3EnzymesIBA
01/2016 - 06/2005
3Doxorubicin (Adriamycin)FDA LinkGeneric
01/2016 - 06/2005
3Dasatinib (BMS 354825)FDA Link
01/2015 - 05/2007
3Rituximab (Mabthera)FDA Link
11/2014 - 10/2006
3Death Domain ReceptorsIBA
10/2014 - 05/2010
3Phosphodiesterase 5 InhibitorsIBA
10/2014 - 03/2014
3Histones (Histone)IBA
09/2014 - 01/2004

Therapy/Procedure

48Therapeutics
07/2020 - 01/2003
11Drug Therapy (Chemotherapy)
06/2014 - 02/2003
5Radiotherapy
02/2012 - 07/2003